Antihypertensive and hypolipidemic efficacy of triple fixed-dose combinations based on perindopril: INTEGRATION II study

The use of fixed-dose combinations for hypertension (HTN) has long been a routine clinical practice. Recently, special attention has been paid to multi-target fixed-dose combinations with the ability to reduce not only blood pressure (BP), but also low-density lipoprotein (LDL) levels. At the same time, there is not much evidence for this approach.

Aim. To evaluate the antihypertensive and lipid-lowering effect of fixed-dose combinations based on perindopril.

Material and methods. The INTEGRATION II study included 9777 patients (mean age 61,8±9,8 years) with HTN and dyslipidemia (DLP), who were prescribed a fixeddose antihypertensive combination of perindopril+amlodipine+indapamide (Co-Dalneva®) in combination with rosuvastatin (Roxera®) (n=5128) or a multi-target fixed-dose combination of perindopril+indapamide+rosuvastatin (Roxatenz-inda) (n=4649).

Results. In the Co-Dalneva® + Roxera® group, a decrease in systolic BP from 164,9±13,8 mm Hg to 127,2±8,8 mm Hg was noted over 12‑week treatment, diastolic BP — from 94,2±10,0 mm Hg to 77,6±6,3 mm Hg; total cholesterol level decreased from 6,2±1,1 mmol/l to 4,3±0,8 mmol/l, and LDL level — from 3,6±1,0 mmol/l to 2,1±0,7 mmol/l. In the Roxatenz-inda group, over the same period, systolic BP decreased from 161,9±12,7 mm Hg to 126,2±8,3 mm Hg, while diastolic BP — from 94,5±9,5 mm Hg to 76,9±6,8 mm Hg. The total cholesterol level decreased from 6,3±1,1 mmol/l to 4,4±0,8 mmol/l; the LDL level — from 3,5±1,0 mmol/l to 2,1±0,6 mmol/l. Both physicians and patients rated Likert scale satisfaction with therapy as very good (4,75-4,8 out of 5), while the compliance according to the patient corresponds to high and highest.

Conclusion. The results of the INTEGRATION II study demonstrated the efficacy and convenience of fixed-dose combinations of antihypertensive and lipid-lowering agents based on perindopril and rosuvastatin in practice. There are good tolerability and a high level of satisfaction with the treatment from both the patient’s and the phusician’s perspective.

1. Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874-2071. doi:10.1097/HJH.0000000000003480.

2. Kobalava ZhD, Konradi AO, Nedogoda SV, et al. 2024 Clinical practice guidelines for Hypertension in adults. Russian Journal of Cardiology. 2024;29(9):6117. (In Russ.) doi:10.15829/1560-4071-2024-6117. EDN GUEWLU.

3. Shalnova SA, Yarovaya EB, Metelskaya VA, et al. The relationship of arterial hypertension, elevated low-density lipoprotein cholesterol and their combination with the occurrence of new cases of cardiovascular diseases in men and women of working age. Rational Pharmacotherapy in Cardiology. 2024;20(2):183-93. (In Russ.) doi:10.20996/1819-6446-2024-3013. EDN IWKEIT.

4. Maksimov ML, Ermolaeva AS, Dralova OV. Advantages and novelty of clinical application of the triple combination for arterial hypertension with dyslipidemia: ace inhibitor perindopril with rosuvastatin and indapamide. Russian Journal of Cardiology. 2017;(7):139-50. (In Russ.) doi:10.15829/1560-4071-2017-7-139-150.

5. Drapkina OM, Lishuta AS. Using a combination of perindopril, indapamide and rosuvastatin in the treatment of patients with hypertension and dyslipidemia. Rational Pharmacotherapy in Cardiology. 2017;13(4):454-62. (In Russ.) doi:10.20996/1819-6446-2022-06-08.

6. Mazza A, Lenti S, Schiavon L, et al. Fixed-Dose Triple Combination of Antihypertensive Drugs Improves Blood Pressure Control: From Clinical Trials to Clinical Practice. Adv Ther. 2017;34(4):975-85. doi:10.1007/s12325-017-0511-1.